(en) [Metformin revisited and consolidated in 2016: A consensual point of view from Africa to Europe] Metformin is still in 2016 the first choice treatment in type 2 diabetes. A substantial number of studies have reported cardiovascular benefits and, more recently, a reduction in cancer risk.
Buysschaert, M., Djorolo, F., Amousso-Guenou, D., Lokrou, A., Preumont, V., Buysschaert, B., & Diop, S. N. (2016). La metformine revisitée et consolidée en 2016 : un point de vue consensuel de l’Afrique à l’Europe. Médecine des Maladies Métaboliques, 10(2), 151-154. https://hdl.handle.net/2078.5/185245 (Original work published 2016)